MITFY yields 2.58% · JNJ yields 2.14%● Live data
📍 MITFY pulled ahead of the other in Year 1
Combined, MITFY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MITFY + JNJ for your $10,000?
Mitie Group plc, together with its subsidiaries, provides strategic outsourcing services in the United Kingdom and internationally. The company operates in eight segments: Business Services, Technical Services, Central Government & Defense (CG&D), Communities, Care & Custody, Landscapes, Waste, and Spain. The company provides security services, such as manned guarding and technology-backed monitoring solutions, fire and security systems installations, vetting and front-of-house services; and general, specialist, and technical cleaning services in offices, buildings, transport and logistics hubs, and high-security environments. It is also involved in the provision of technology-backed engineering; maintenance, repair, and mechanical and electrical project activities; energy, carbon, and water management services; air conditioning and disinfection solutions; telecoms and energy services; and remote asset monitoring, and digital and connected workplace solutions. In addition, the company provides facilities management services across central government and defense contracts; decarbonization solutions; and engineering services. Further, it offers integrated facilities management services to devolved public sector customers, which focuses on community environments in healthcare, schools and universities, emergency services, and local authorities; portering services; public services in immigration, criminal justice, and healthcare; horticultural and winter landscaping services; and waste elimination, reduction, recycling, and treatment solutions. Mitie Group plc was incorporated in 1936 and is headquartered in London, the United Kingdom.
Full MITFY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.